(December 3, 2018, 12:52 PM EST) -- WASHINGTON, D.C. — Arguments about whether the Food and Drug Administration rejected a stronger warning about leg fractures on the label of the osteoporosis drug Fosamax will be heard by the U.S. Supreme Court on Jan. 7, according to an argument schedule released Dec. 3 (Merck Sharp & Dohme Corp. v. Doris Albrecht, et al., No. 17-290, U.S. Sup.)....